Back to top
more

Synergy Pharmaceuticals, Inc. (SGYP)

(Delayed Data from NSDQ)

$0.03 USD

0.03
NA

0.00 (0.00%)

Updated Mar 7, 2019 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Amgen, Valeant Pharmaceuticals International, Celgene and Lexicon Pharmaceuticals

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Amgen, Valeant Pharmaceuticals International, Celgene and Lexicon Pharmaceuticals

    Arpita Dutt headshot

    4 FDA Decisions to Watch Out for in Feb 2017

    by Arpita Dutt

    So far this year, the FDA has approved one drug. Will the pace of drug approvals pick up in February?

      Ironwood-Allergan Linzess Gets FDA Approval in Lower Dose

      by Zacks Equity Research

      Ironwood Pharmaceuticals, Inc. (IRWD) and partner Allergan plc (AGN) announced that the FDA has approved a lower dose strength of Linzess (linaclotide) ??? 72 mcg ??? for the treatment of adult patients with chronic idiopathic constipation (CIC).

        Are Options Traders Betting on a Big Move in Synergy Pharmaceuticals (SGYP) Stock?

        by Zacks Equity Research

        Investors in Synergy Pharmaceuticals Inc. (SGYP) need to pay close attention to the stock based on moves in the options market lately.

          Synergy (SGYP) Trulance Wins FDA Approval for Constipation

          by Zacks Equity Research

          Synergy Pharmaceuticals Inc. (SGYP) announced that the FDA has approved one of its lead pipeline candidates, Trulance (plecanatide), for the treatment of adults suffering from chronic idiopathic constipation (CIC).

            Key FDA Events to Watch Out for in Q1

            by Zacks Equity Research

            Two important regulatory events scheduled in the first quarter of 2017.

              Zacks.com featured highlights: Beazer Homes USA, EnerSys, Greenhill, Synergy Pharmaceuticals and Movado Group

              by Zacks Equity Research

              Zacks.com featured highlights: Beazer Homes USA, EnerSys, Greenhill, Synergy Pharmaceuticals and Movado Group

                5 Stocks to Play on New Analyst Coverage

                by Zacks Equity Research

                As analysts are one of the most important information intermediaries in capital markets, initiation of coverage by them creates value for companies. So, it???s a good strategy to bet on stocks that have seen increased analyst coverage over the last few weeks.

                  Arpita Dutt headshot

                  Two Key FDA Decisions to Watch Out for in January 2017

                  by Arpita Dutt

                  Incyte (INCY) and Synergy (SGYP) have important regulatory events coming up this month.

                    Synergy Reports Positive Top-Line Phase III Data on IBS Drug

                    by Zacks Equity Research

                    Synergy Pharmaceuticals announced positive top-line data from a pivotal phase III study evaluating the efficacy and safety of its investigational drug, plecanatide, for the treatment of adult patients suffering from irritable bowel syndrome.